Ali Hosni
@Dr_AliHosni
Followers
398
Following
2K
Statuses
147
Husband, Dad, Radiation oncologist, Clinician Scientist, and life long learner. Everybody deserves a smile
Joined April 2013
RT @CJTsaiMDPhD: 🆕📢 Can patients with bone mets benefit from structured exercise regimen after radiation? The EXERT-BM trial, led by our j…
0
4
0
Exciting news: 1st pnt enrolled #ULTRAS. 1st multicenter MRgRT ph3 RCT for liver met. Single Fx SBRT: BED10 180 vs 100 to improve LC. @aguilera_md @Sunnybrook @teo_stanescu @Hendo_tan @IssaMohamadRad @SweetPingNg @MichaelYanMD @ldawsonmd @DKirschMDPhD @mr_linac @Xristodouleas
1
11
52
0
0
1
@ldawsonmd @aallam_mo @NiuSanford @nbn426 @jryckman3 @safaviaa @lauren_henke @KrishanJethwa @MichaelYanMD We will work on this soon
0
0
10
@BadrIdsaid @pmcancercentre @DKirschMDPhD Great work @ZHusainMD @DrTonyEskander. @BadrIdsaid has done great work that is being validated in such large cohort.
0
0
4
1
0
1
RT @UHN: #TeamUHN Drs. Erin Watson & Ali Hosni from UHN's @pmcancercentre led a research team to transform the way we classify and understa…
0
7
0
@RadMedPM @pmcancercentre @DrBezjakRO @ASTRO_org @thePMCF @PMResearch_UHN @UHN @UHN_Research @UofTDRO @DKirschMDPhD Very well-deserved
0
0
0
@KaramLab @CJTsaiMDPhD @ClevelandClinic @xrtGenomics @imrtlee @seanmmcbride @YaoCMKL @yaoyu_md @Esanzgarcia @DrMLChua @Dealmakertech @DanielMaMD @ScottBratman @JJCaudell @safaviaa @HenryParkMD @ajuloorimd The #SELECT phase III RCT using SPECT CT to SELECT patient who would benefit from unilateral RT for OPC, is another exciting alternative option of potentially reaching to zero dose to contralateral neck @DrJohndeAlmeida
0
0
8
The #ULTRAS trial collaborators are so excited to start accrual soon @aguilera_md @Sunnybrook @teo_stanescu @Hendo_tan @GI_RadOnc @Issa10079384 @Xristodouleas @MichaelYanMD @SweetPingNg @RMPCRProgram @RadMedPM
The ULTRAS trial will shortly start recruiting patients with liver metastases led by Dr Ali Hosni from Princess Margaret Hospital, Toronto. The clinical hypothesis being investigated is whether a higher single dose of MRgRT improves local control in patients with liver mets
3
7
36
@CJTsaiMDPhD @imrtlee @MSK_RadOnc @MSKCancerCenter Great work, and speaks up for radiobiology behind impact of accelerated repopulation, doubling time, OTT, and intrinsic radiosenstivity on tBED. Adding to all of this, the use of personalized novel hypoxia imaging biomarker !!! Let's do phase III RCT to change the practice !!!!
0
0
7
0
0
2
@CJTsaiMDPhD @ScottBratman @ezrahahn Working with the team to get this done as a clinical trial, hopefully soon, stay tuned !!
0
0
4
@_ShankarSiva @MikeChuongMD @jryckman3 @HenningWillers @DrewMoghanaki @ldawsonmd @CancerConnector @F_Fintelmann_MD @aguilera_md @SweetPingNg @Hendo_tan @whallradonc @GI_RadOnc Thx @_ShankarSiva We will hopefully present the details of trial design on the @mr_linac consortium meeting @Xristodouleas
0
0
3
@DrewMoghanaki @MikeChuongMD @jryckman3 @HenningWillers @ldawsonmd @_ShankarSiva @CancerConnector @F_Fintelmann_MD @aguilera_md @SweetPingNg @Hendo_tan @whallradonc @GI_RadOnc @sueyom Agree, we need to get a consensus guidelines for sbrtRECIST, and publish it, so can be used for clinical trials, and updated in the future whenever needed @sueyom
1
0
5
@DrewMoghanaki @MikeChuongMD @jryckman3 @HenningWillers @ldawsonmd @_ShankarSiva @CancerConnector @F_Fintelmann_MD @aguilera_md @SweetPingNg @Hendo_tan @whallradonc @GI_RadOnc Yep, come and join us. You are thinking same way we do!!
1
0
0
@DrewMoghanaki @MikeChuongMD @jryckman3 @HenningWillers @ldawsonmd @_ShankarSiva @CancerConnector @F_Fintelmann_MD @aguilera_md @SweetPingNg @Hendo_tan @whallradonc @GI_RadOnc Excellent point. The #ULTRAS TSC is actually adopting a modified version, when the treated lesion with single Fx will be the only target lesion. Then we will assess LC based on the target lesion, then we also assess intra and exteahepatic progression outside the target lesion
1
0
0
@DrewMoghanaki @MikeChuongMD @jryckman3 @HenningWillers @ldawsonmd @_ShankarSiva @CancerConnector @F_Fintelmann_MD @aguilera_md @SweetPingNg @Hendo_tan @whallradonc @GI_RadOnc We will use standard imaging with RECIST criteria
1
0
0
@MikeChuongMD @jryckman3 @HenningWillers @DrewMoghanaki @ldawsonmd @_ShankarSiva @CancerConnector @F_Fintelmann_MD @aguilera_md @SweetPingNg @Hendo_tan @whallradonc @GI_RadOnc - Primary end point is local control of treated liver mets. - Only cancer with high a/b ratio eg. CRC, pancreas, HN SCC, cervix SCC, skin SCC, and NSCLC) - 1-3 lesions - 114 patients in total
1
0
6